LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Munjal Mahendrabhai Patel & Others LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Munjal Mahendrabhai Patel & PACs LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ashish Rajanbhai Patel & PACs Lincoln Pharmaceuticals Ltd - 531633 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclosed herewith the copies of published newspaper advertisement with respect to the un-audited financial results (standalone and consolidated) of the Company for the quarter ended June 30, 2021. The said advertisement was published in the following newspapers: 1) The Economic Times, Ahmedabad Edition - In English; 2) Jay Hind, Ahmedabad Edition - In Gujarati. Lincoln Pharmaceuticals Q1 standalone net up 16 per cent
Will introduce new products to domestic market, and expects approvals for export market LINCOLN PHARMACEUTICALS LTD. - 531633 - Financial Result For The Quarter Ended June 30, 2021
We would like to inform that the Board of Directors of the Company at its meeting held today i.e. Tuesday, August 10, 2021, have considered and approved the un-audited financial results of the Company (Standalone and Consolidated) along with the limited review report for the quarter ended on June 30, 2021. Further, we enclose herewith financial highlights of the Company for the aforesaid quarter. LINCOLN PHARMACEUTICALS LTD. - 531633 - Board Meeting Outcome for Outcome Of The Board Meeting
We would like to inform that the Board of Directors of the Company at its meeting held today i.e. Tuesday, August 10, 2021, have considered and approved the un-audited financial results of the Company (Standalone and Consolidated) along with the limited review report for the quarter ended on June 30, 2021. Further, we enclose herewith financial highlights of the Company for the aforesaid quarter. Lincoln Pharmaceuticals Ltd - 531633 - Board Meeting Intimation for Consider And Approve The Un-Audited Financial Results For The Quarter Ended On June 30, 2021.
LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2021 ,inter alia, to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter ended on June 30, 2021 along with any other business, if any. Pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, trading window has been closed for trading in securities of the Company from July 01, 2021 and shall reopen after the expiry of 48 hours from the time the result becomes generally available. LINCOLN PHARMACEUTICALS LTD. - 531633 - Shareholding for the Period Ended June 30, 2021
Lincoln Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here Lincoln Pharmaceuticals Ltd - 531633 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to provision of Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 2018, we hereby submit the confirmation certificate received from Link Intime India Private Limited, Registrar and Share Transfer Agent (RTA) for the Quarter Ended June 30, 2021.